bioAffinity Technologies Secures U.S. Patent For Novel siRNA Composition Targeting CD320 And LRP2 Cell Receptors To Selectively Kill Cancer Cells, Advancing Research On Topical Treatments For Skin Cancers And Expanding Therapeutic Portfolio Covering Lung, Breast, Prostate, Brain, And Skin Malignancies With Noninvasive Targeted Approach

Simultaneous siRNA Knockdown of Specific Cell Receptors Shown to Selectively Kill Cancer

Company Research Targets Topical Application for Treatment of Skin Cancers

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering a novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane.

The patent, "Compositions and Methods for Treating Cancer," (Patent No. 12,305,171) provides for use of the novel therapeutic approach with cancers of the lung, breast, prostate, brain and skin. Research has begun toward development of a topical treatment for cutaneous malignancies and neoplasms of the skin.

The therapeutic patent is an important addition to bioAffinity Technologies' patent portfolio, which includes 19 awarded U.S. and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics.

The invention uses small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies demonstrated that the double knockdown of the proteins using siRNAs is selectively cytotoxic to human cancer cells but does not kill normal cells under the same treatment.